The Korean Journal of Internal Medicine10.3904/kjim.2016.2052019343579-587Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patientsDa Hea Seo, Yongin Cho, Sujin Lee, Seho Park, Seung-Il Kim, Byeong Woo Park, Yumie Rhee,,
The Breast10.1016/s0960-9776(07)70050-4200716S8S27 Application of aromatase inhibitors in endocrine responsive breast cancersP.E. Goss,
The Breast10.1016/j.breast.2007.07.011200716114-119Application of aromatase inhibitors in endocrine responsive breast cancersPaul Goss, Melinda Wu,
The Breast10.1016/j.breast.2019.01.010201945119Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancerKai Zhang, Qilin Tang,
Clinical Breast Cancer10.3816/cbc.2009.n.037200994219-224Sexual Dysfunction and Aromatase Inhibitor Use in Survivors of Breast CancerKaren W. Kwan, Rowan T. Chlebowski,
Breast Cancer Research10.1186/bcr2543201012S1Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancerS Weeraman, C Hunsley, M Wall, R Kirby,,
European Journal of Cancer Supplements10.1016/s1359-6349(06)80377-0200642152Amenorrhea as a prognostic factor in premenopausal endocrine responsive early breast cancer patientsT. Globokar, Snoj, A. Sadikov, T. Cufer,
Breast Cancer Research10.1186/bcr154620068S2Evolution of aromatase inhibitors as an endocrine treatment for breast cancerWR Miller,,
Clinical Breast Cancer10.3816/cbc.2004.s.00920045S13-S17Switching Trial of Adjuvant Tamoxifen with an Aromatase Inhibitor in Postmenopausal Patients with Breast CancerFrancesco Boccardo,
Breast Cancer Research and Treatment10.1007/s10549-018-05086-820191743785-794Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivorsXiaoqing Xu, Rowan T. Chlebowski, Jiaxiao Shi, Ana Barac, Reina Haque,,